Kempharm Financial Statements From 2010 to 2021

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Kempharm financial statements provide useful quarterly and yearly information to potential Kempharm investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Kempharm financial statements helps investors assess Kempharm's valuation, profitability, and current liquidity needs.
We have found seventy-one available fundamental ratios for Kempharm, which can be analyzed and compared to other ratios and to its peers in the industry. Please verify all of Kempharm last-minute fundamental drivers against the trend between 2010 and 2021 to make sure the company can sustain itself down the road.
Kempharm Invested Capital is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital was reported at 69.7 Million. The current Invested Capital Average is estimated to increase to about 20.1 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to (8.3 M).

Search Financial Statements 

 
Refresh
Check Kempharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kempharm main balance sheet or income statement drivers, such as Gross Profit of 14.6 M, Interest Expense of 4.7 M or Operating Expenses of 26.1 M, as well as many exotic indicators such as Asset Turnover of 1.26, Current Ratio of 1.14 or Gross Margin of 0.89. Kempharm financial statements analysis is a perfect complement when working with Kempharm Valuation or Volatility modules. It can also supplement various Kempharm Technical models. Please see the analysis of Kempharm Correlation against competitors.

Kempharm Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets11.5 M11.2 M22.9 M
Increasing
Stable
Cash and Equivalents4.4 M4.3 M9.3 M
Increasing
Stable
InvestmentsM2.9 M18.4 M
Decreasing
Slightly volatile
Investments CurrentM2.9 M17.4 M
Decreasing
Slightly volatile
Investments Non CurrentM2.9 M6.2 M
Decreasing
Slightly volatile
Property Plant and Equipment Net2.1 M2.4 M1.3 M
Increasing
Slightly volatile
Trade and Non Trade Receivables2.3 M2.6 M3.7 M
Decreasing
Slightly volatile
Trade and Non Trade Payables6.7 M6.6 M4.5 M
Increasing
Slightly volatile
Total Liabilities82.9 M77.6 M57.3 M
Increasing
Slightly volatile
Current Assets8.6 M8.4 M20 M
Increasing
Stable
Assets Non Current3.7 M2.8 MM
Increasing
Slightly volatile
Current Liabilities8.4 M7.5 M7.1 M
Increasing
Slightly volatile
Liabilities Non Current74.5 M70.1 M50.2 M
Increasing
Slightly volatile
Total Debt70.5 M70.4 M45.4 M
Increasing
Slightly volatile
Debt Current735.9 K717 K2.4 M
Decreasing
Slightly volatile
Debt Non Current68.9 M69.6 M42.9 M
Increasing
Slightly volatile
Cash and Equivalents USD4.4 M4.3 M9.3 M
Increasing
Stable
Total Debt USD70.5 M70.4 M45.4 M
Increasing
Slightly volatile

Kempharm Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues14.6 M13.3 M13 M
Increasing
Slightly volatile
Selling General and Administrative Expense9.4 M7.9 M7.2 M
Increasing
Slightly volatile
Research and Development Expense9.1 M8.8 M13.3 M
Increasing
Slightly volatile
Operating Expenses26.1 M18.9 M21.9 M
Increasing
Slightly volatile
Interest Expense4.7 M4.8 MM
Increasing
Slightly volatile
Income Tax Expense(36.7 K)(34 K)(29.4 K)
Decreasing
Slightly volatile
Weighted Average Shares4.3 MM1.2 M
Increasing
Slightly volatile
Weighted Average Shares Diluted4.3 MM1.2 M
Increasing
Slightly volatile
Revenues USD14.6 M13.3 M13 M
Increasing
Slightly volatile
Gross Profit14.6 M13.3 M13 M
Increasing
Slightly volatile

Kempharm Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and DisposalsM3.7 M(7.3 M)
Increasing
Slightly volatile
Net Cash Flow from Financing2.8 M2.7 M16.6 M
Increasing
Very volatile
Issuance Repayment of Debt Securities 2.9 M2.8 M9.4 M
Decreasing
Very volatile
Issuance Purchase of Equity Shares22.8 M25.6 M38.9 M
Decreasing
Slightly volatile
Net Cash Flow from Investing(35.6 K)(33 K)(104.8 K)
Increasing
Stable
Net Cash Flow or Change in Cash and Cash Equivalents827.6 K767 K74 K
Decreasing
Stable
Share Based Compensation3.3 M2.5 M2.6 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion262.3 K273 K175.4 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity0.20.1960.8908
Decreasing
Stable
Gross Margin0.890.90.9829
Decreasing
Slightly volatile
Asset Turnover1.261.2180.9675
Increasing
Slightly volatile
Sales per Share3.913.3386.3769
Decreasing
Slightly volatile
Price to Sales Ratio2.993.3551.2589
Increasing
Slightly volatile
Current Ratio1.141.1122.6124
Increasing
Stable
Tangible Assets Book Value per Share2.892.81638.4621
Decreasing
Stable

Kempharm Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization61.8 M50.8 M166.4 M
Decreasing
Slightly volatile
Enterprise Value118.9 M114 M184 M
Decreasing
Slightly volatile
Invested Capital77 M69.7 M52.6 M
Increasing
Slightly volatile
Average Assets11.2 M10.9 M26.6 M
Increasing
Stable
Invested Capital Average20.1 M19.6 M46.6 M
Increasing
Slightly volatile
Tangible Asset Value11.5 M11.2 M22.9 M
Increasing
Stable
Working Capital868.3 K846 K13 M
Increasing
Stable

Kempharm Fundamental Market Drivers

Short Percent Of Float12.52%
Forward Price Earnings358.67
Shares Short Prior Month3.21M
Average Daily Volume Last 10 Day520.68k
Average Daily Volume In Three Month838.98k
Date Short Interest28th of May 2021
Fifty Day Average12.91
Two Hundred Day Average10.07

Kempharm Upcoming Events

Upcoming Quarterly Report11th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

About Kempharm Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kempharm income statement, its balance sheet, and the statement of cash flows. Kempharm investors use historical funamental indicators, such as Kempharm's revenue or net income, to determine how well the company is positioned to perform in the future. Although Kempharm investors may use each financial statement separately, they are all related. The changes in Kempharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kempharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kempharm Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kempharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Revenues13.3 M14.6 M
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Kempharm Investors Sentiment

The influence of Kempharm's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kempharm. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - KMPH

Kempharm Investor Sentiment

Most of Macroaxis users are now bullish on Kempharm. What is your trading attitude regarding investing in Kempharm? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kempharm Correlation against competitors. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.